Lymph Node News and Research

RSS

Lymph is clear or white fluid that travels through vessels, moves within tissues and work to keep all the parts of the body clean. After passing through the channels of the lymphatic system they drain into the lymph nodes. The lymph nodes act as filters along the lymphatic system. These nodes trap germs like bacteria, viruses, toxins as well as cancer cells and ensure that these are removed from the body.

Tool guides lymph node surgery in Asian prostate cancer patients

Researchers from Korea have developed a nomogram that predicts which Asian men with prostate cancer are most at risk for lymph node (LN) invasion.

30 Sep 2013

Use of SHOX2 DNA measurement improves cancer staging tools

Findings indicate that assessment of SHOX2 DNA methylation level in lymph node tissue improves the negative predictive value of endobronchial ultrasound with transbronchial needle aspiration, as well as endoscopic lung cancer staging in general.

30 Sep 2013

Mayo Clinic experts to discuss risk factors, screening and treatments for breast cancer

October is National Breast Cancer Awareness Month, and Mayo Clinic breast cancer experts are available to discuss risk factors, screening and treatments.

27 Sep 2013

miR-31 in primary tumor cells predicts lymph node metastasis in NSCLC patients

Determining whether a patient's lung cancer has spread to nearby lymph nodes is critical for identifying the most effective therapy, but it usually requires surgery. A new study suggests, however, that measuring levels of a particular molecule in a sample of tumor tissue might accurately answer the question.

25 Sep 2013

Immune marker prognostic after non-clear cell RCC surgery

The preoperative neutrophil-to-lymphocyte ratio is associated with disease-free survival in patients undergoing resection of localized non-clear cell renal cell carcinoma, research shows.

24 Sep 2013

GGO-dominant lung tumors have excellent prognosis

Ground glass opacity-dominant clinical stage IA lung adenocarcinoma is a low-grade malignancy with an “excellent” prognosis, Japanese researchers believe.

10 Sep 2013

Enhanced recovery pathway recovers patients undergoing gynecologic surgery more quickly

Patients who had complex gynecologic surgery managed by an enhanced recovery pathway resulted in decreased narcotic use, earlier discharge, stable readmission rates, excellent patient satisfaction and cost savings, according to a Mayo Clinic study.

27 Aug 2013

Enhanced recovery pathway for patients undergoing gynecologic surgery recovers more quickly

Patients who had complex gynecologic surgery managed by an enhanced recovery pathway (ERP) resulted in decreased narcotic use, earlier discharge, stable readmission rates, excellent patient satisfaction and cost savings, according to a Mayo Clinic study. The findings are published in the journal Obstetrics & Gynecology.

27 Aug 2013

Tufts Health Plan provides positive coverage decision and in-network provider status to bioTheranostics

bioTheranostics, a leading provider of molecular diagnostic solutions for cancer, has received a positive coverage decision and in-network provider status from Tufts Health Plan for its CancerTYPE ID molecular cancer classifier.

23 Aug 2013

FDA grants Orphan Drug Designation to ADXS-HPV for treatment of HPV-associated anal cancer

Advaxis, Inc., (OTCQB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus (HPV)-associated anal cancer.

17 Aug 2013

Study shows lymph node location influences maturation process of cells they contain

Based on their observations, the scientists deduced that lymph node location influences the maturation process of the cells they contain. "The cells retained their original skills for weeks following the transplant," says Dr. Sascha Cording, one of the study's first authors. "You might say lymph nodes have something like a location-specific memory."

17 Aug 2013

High mobility group (HMG) genes and cancer: an interview with Dr. Linda Resar, Johns Hopkins University School of Medicine

High mobility group A genes are highly expressed in all aggressive cancers studied to date. These genes encode the high mobility group A (HMGA) proteins. In other words, these genes provide the genetic “code” necessary to produce HMGA proteins.

8 Aug 2013

Breast cancer survivors are more likely to develop debilitating disorder arm lymphoedema

Breast cancer survivors who have extensive surgery are four times more likely to develop the debilitating disorder arm lymphoedema, a QUT study has found.

8 Aug 2013

Castle Biosciences to present DecisionDx-Melanoma test data at Summer Academy Meeting of AAD

Castle Biosciences Inc. announced that data from studies of its DecisionDx-Melanoma test are being presented today at the Summer Academy Meeting of the American Academy of Dermatology. The validation data confirm previous studies showing that the gene expression profile test is a strong independent predictor for classifying which Stage I or II non-metastatic cutaneous melanoma patients will likely recur.

2 Aug 2013

Innovative microsurgery technique helps prevent lymphedema in patients with breast cancer

A team of surgeons and members of the breast cancer program of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center is conducting a two-year pilot study of an innovative microsurgery technique coupled with imaging technology to not only prevent lymphedema but also potentially detect and treat it early.

24 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.

11 Jul 2013

Robotic retroperitoneal lymph node dissection (RPLND) for testicular cancer: an interview with Dr. Stephen Williams of St. Joseph Hospital in Orange

Robotic RPLND utilizes laparoscopy combined with robotic technology to perform dissection and removal of lymph node tissue in the retroperitoneum both as a staging as well as therapeutic procedure for patients with testicular cancer.

10 Jul 2013

Biomarker indicates which women are at risk for breast cancer recurrence after tamoxifen

A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen-receptor (ER)-positive breast cancer should receive a second estrogen-blocking medication after completing tamoxifen treatment.

30 Jun 2013

Study: Active surveillance does not appear to be good idea for black men with prostate cancer

A Johns Hopkins study of more than 1,800 men ages 52 to 62 suggests that African-Americans diagnosed with very-low-risk prostate cancers are much more likely than white men to actually have aggressive disease that goes unrecognized with current diagnostic approaches.

26 Jun 2013